WO2004033431A3 - Hydroxypyrazoles for use against metabolic-related disorders - Google Patents

Hydroxypyrazoles for use against metabolic-related disorders Download PDF

Info

Publication number
WO2004033431A3
WO2004033431A3 PCT/US2003/031509 US0331509W WO2004033431A3 WO 2004033431 A3 WO2004033431 A3 WO 2004033431A3 US 0331509 W US0331509 W US 0331509W WO 2004033431 A3 WO2004033431 A3 WO 2004033431A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
present
compounds
related disorders
enhancers
Prior art date
Application number
PCT/US2003/031509
Other languages
French (fr)
Other versions
WO2004033431A2 (en
Inventor
Graeme Semple
Young Jun Shin
Original Assignee
Arena Pharm Inc
Graeme Semple
Young Jun Shin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc, Graeme Semple, Young Jun Shin filed Critical Arena Pharm Inc
Priority to AU2003282679A priority Critical patent/AU2003282679A1/en
Publication of WO2004033431A2 publication Critical patent/WO2004033431A2/en
Publication of WO2004033431A3 publication Critical patent/WO2004033431A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention relates to certain hydroxypyrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmaceutical properties, for example as agonists for the nicotinic acid receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
PCT/US2003/031509 2002-10-04 2003-10-02 Hydroxypyrazoles for use against metabolic-related disorders WO2004033431A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003282679A AU2003282679A1 (en) 2002-10-04 2003-10-02 Hydroxypyrazoles for use against metabolic-related disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41619302P 2002-10-04 2002-10-04
US60/416,193 2002-10-04
US41712002P 2002-10-07 2002-10-07
US60/417,120 2002-10-07

Publications (2)

Publication Number Publication Date
WO2004033431A2 WO2004033431A2 (en) 2004-04-22
WO2004033431A3 true WO2004033431A3 (en) 2004-07-29

Family

ID=32096141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031509 WO2004033431A2 (en) 2002-10-04 2003-10-02 Hydroxypyrazoles for use against metabolic-related disorders

Country Status (2)

Country Link
AU (1) AU2003282679A1 (en)
WO (1) WO2004033431A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
EP1633351A1 (en) * 2003-06-13 2006-03-15 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
JP2007512346A (en) 2003-11-21 2007-05-17 アリーナ ファーマシューティカルズ， インコーポレイテッド 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treating disorders related to their metabolism
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
PE20060949A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
JP2010518014A (en) * 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド 2-Aminopyridine derivatives useful as kinase inhibitors
RU2011123647A (en) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед COMPOUNDS USEFUL AS ATR KINASE INHIBITORS
PT3354650T (en) 2008-12-19 2022-06-20 Vertex Pharma Compounds useful as inhibitors of atr kinase
JP2013526540A (en) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
MX2012013081A (en) 2010-05-12 2013-05-09 Vertex Pharma Compounds useful as inhibitors of atr kinase.
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN102947272A (en) 2010-05-12 2013-02-27 沃泰克斯药物股份有限公司 2 -aminopyridine derivatives useful as inhibitors of atr kinase
EP2569286B1 (en) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2569289A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX2013011450A (en) 2011-04-05 2014-02-03 Vertex Pharma Aminopyrazine compounds useful as inhibitors of tra kinase.
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014522818A (en) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
MX2014003796A (en) 2011-09-30 2015-01-16 Vertex Pharma Compounds useful as inhibitors of atr kinase.
IN2014CN02501A (en) 2011-09-30 2015-06-26 Vertex Pharma
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2015515478A (en) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinases and combinations thereof
CN104780915A (en) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PL3808749T3 (en) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
JP6543252B2 (en) 2013-12-06 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 2-Amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] pyrazolo [1,5-a] pyrimidine-3-carboxamide compounds useful as ATR kinase inhibitors, their preparation, their different solid forms And radiolabeled derivatives
MX2016015874A (en) 2014-06-05 2017-03-27 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyrid in-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof.
PT3157566T (en) 2014-06-17 2019-07-11 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (en) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1)
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
KR20190116416A (en) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. Compounds and Methods for Treating Primary Bile Cholangitis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS549279A (en) * 1977-06-24 1979-01-24 Ishihara Sangyo Kaisha Ltd Tetrazolypyridylketone and herbicides coatining the same
US4857542A (en) * 1985-05-20 1989-08-15 Mitsubishi Chemical Industries Limited Prophylactic and therapeutic composition for circulatory disorders and method of treatment
JPH0338586A (en) * 1989-07-04 1991-02-19 Nippon Soda Co Ltd Substituted pyridine derivative, its production and herbicide
US5183825A (en) * 1992-04-07 1993-02-02 American Home Products Corporation 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use
WO2001094339A1 (en) * 2000-06-09 2001-12-13 Syngenta Participations Ag Substituted pyridine herbicides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS549279A (en) * 1977-06-24 1979-01-24 Ishihara Sangyo Kaisha Ltd Tetrazolypyridylketone and herbicides coatining the same
US4857542A (en) * 1985-05-20 1989-08-15 Mitsubishi Chemical Industries Limited Prophylactic and therapeutic composition for circulatory disorders and method of treatment
JPH0338586A (en) * 1989-07-04 1991-02-19 Nippon Soda Co Ltd Substituted pyridine derivative, its production and herbicide
US5183825A (en) * 1992-04-07 1993-02-02 American Home Products Corporation 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use
WO2001094339A1 (en) * 2000-06-09 2001-12-13 Syngenta Participations Ag Substituted pyridine herbicides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NISHIYAMA, RYUZO ET AL: "Pyrazolyl pyridyl ketones", XP002271467, retrieved from STN Database accession no. 90:186940 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; UEDA, AKIYOSHI ET AL: "Preparation of pyrazolylpyridine derivatives as herbicides", XP002271466, retrieved from STN Database accession no. 115:29323 CA *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Also Published As

Publication number Publication date
AU2003282679A1 (en) 2004-05-04
WO2004033431A2 (en) 2004-04-22
AU2003282679A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2004033431A3 (en) Hydroxypyrazoles for use against metabolic-related disorders
WO2006069242A3 (en) Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders
TNSN06150A1 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2006017836A3 (en) 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)
WO2006124490A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2006011050A3 (en) Pyridine derivatives
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
WO2003063864A3 (en) Heterocyclic compounds which are active as inhibitors of beta lactamases
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
NO20070445L (en) Pyrimidine.
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
NO20051901L (en) New antimycobacterial compositions and pyrrole derivatives such as antimycobacterial compositions
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
HK1097474A1 (en) Carbostyril derivatives for accelerating salivation
MY148529A (en) Formulations of quinolinones
JP5765738B2 (en) Rosuvastatin and atorvastatin derivatives
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
WO2007063384A3 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
DE60327446D1 (en) 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLISM DISORDERS, SUCH AS e.g. dyslipidemia
GEP20084406B (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
WO2005051937A3 (en) 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
WO2005118558A3 (en) Pyrimidine compounds and use thereof
WO2005100322A8 (en) Sulphur-linked imidazole compounds for the treament of hiv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP